Medication-related osteonecrosis of the jaws (MRONJ) is a well-known side effect of bisphosphonate drugs used in the treatment of osteometabolic disorders and some types of cancer. However, development of MRONJ have also been reported in patients using denosumab, a monoclonal immunoglobulin G2 antibody inhibiting osteoclastic bone resorption. Even though denosumab is more advantageous than bisphosphonates due to its shorter half-life and lack of binding to the bone, MRONJ has accepted as a well-known side-effect of denosumab as it is in bisphosphonates. We reported clinical, radiographic, and histopathological findings of a female patient who developed osteonecrosis of the jaw following denosumab treatment and presented with actinomycosis infection and extensive periosteal new bone formation. Our case emphasized the importance of dental screening before initiating and during denosumab treatment in order to prevent and lower the risk of MRONJ development.
Keywords: Actinomyces; actinomycosis; denosumab; mandible; osteonecrosis
İlaca bağlı çene kemiği osteonekrozu [medication-related osteonecrosis of the jaws (MRONJ)], metabolik kemik hastalıklarının ve bazı kanser tiplerinin tedavisinde kullanılan bisfosfonat grubu ilaçların bilinen bir yan etkisidir. Bununla birlikte osteoklastik kemik rezorpsiyonunu inhibe eden bir monoklonal immünglobulin G2 antikoru olan denosumab kullanan hastalarda da MRONJ gelişimi bildirilmiştir. Denosumab, yarılanma ömrünün daha kısa olması ve kemiğe bağlanmaması nedeniyle bifosfonatlara göre daha avantajlı olsa da günümüzde MRONJ bifosfonat grubu ilaçların yanı sıra denosumabın da bilinen bir yan etkisi olarak kabul görmektedir. Bu olgu raporunda, denosumab tedavisini takiben çene osteonekrozu gelişen ve aktinomikoz enfeksiyonu ile yaygın periosteal yeni kemik oluşumu saptanan bir kadın hastanın klinik, radyografik ve histopatolojik bulguları sunulmaktadır. Olgumuz, MRONJ gelişimini önlemek ve MRONJ gelişim riskini azaltmak amacıyla denosumab tedavisine başlamadan önce ve tedavi sırasında yapılması gereken dental muayenenin önemini vurgulamaktadır.
Anahtar Kelimeler: Aktinomiçes; aktinomikoz; denosumab; mandibula; osteonekroz
- Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022;80(5):920-43. [Crossref] [PubMed]
- Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent. 2021;7(1):47. [Crossref] [PubMed] [PMC]
- Qaisi M, Hargett J, Loeb M, Brown J, Caloss R. Denosumab related osteonecrosis of the jaw with spontaneous necrosis of the soft palate: report of a life threatening case. Case Rep Dent. 2016;2016:5070187. [Crossref] [PubMed] [PMC]
- Kövér Z, Bán Á, Gajdács M, Polgár B, Urbán E. Role of Actinomyces spp. and related organisms in the development of medication-related osteonecrosis of the jaw (MRONJ): Clinical evidence based on a case series. Eur J Microbiol Immunol (Bp). 2023;13(4):125-34. [Crossref] [PubMed] [PMC]
- Russmueller G, Seemann R, Weiss K, Stadler V, Speiss M, Perisanidis C, et al. The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. Sci Rep. 2016;6:31604. [Crossref] [PubMed] [PMC]
- Pichardo SE, Kuypers SC, van Merkesteyn JP. Denosumab osteonecrosis of the mandible: a new entity? A case report. J Craniomaxillofac Surg. 2013;41(4):e65-9. [Crossref] [PubMed]
- Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E. Medication-related osteonecrosis of the jaws: considerations on a new antiresorptive therapy (denosumab) and treatment outcome after a 13-year experience. Int J Dent. 2016;2016:1801676. [Crossref] [PubMed] [PMC]
- Baba A, Goto TK, Ojiri H, Takagiwa M, Hiraga C, Okamura M, et al. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw. Dentomaxillofac Radiol. 2018;47(4):20170323. [Crossref] [PubMed] [PMC]
- Querrer R, Ferrare N, Melo N, Stefani CM, Dos Reis PED, Mesquita CRM, et al. Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review. Support Care Cancer. 2021;29(6):2811-20. Erratum in: Support Care Cancer. 2021. [Crossref] [PubMed]
- Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341-7. [Crossref] [PubMed]
- Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-9. [Crossref] [PubMed]
- Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-22. [Crossref] [PubMed] [PMC]
- Karalis M, Pavlidis TE, Psarras K, Ballas K, Zaraboukas T, Rafailidis S, et al. Effect of experimentally induced liver cirrhosis on wound healing of the post-extraction tooth socket in rats. Eur Surg Res. 2008;40(2):190-6. [Crossref] [PubMed]
- Tagliamento M, Boutros C, Viansone A, Brau JJ, Descols P. Denosumab related osteonecrosis of the jaw: Unusual pattern with periosteal reaction. Eur J Cancer. 2022;166:33-7. [Crossref] [PubMed]
- Langdahl B, Ferrari S, Dempster DW. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2016;8(6):225-35. [Crossref] [PubMed] [PMC]
.: Process List